Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

Abstract We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvo...

Full description

Saved in:
Bibliographic Details
Published in:Open forum infectious diseases Vol. 8; no. 2; p. ofab050
Main Authors: Seftel, David, Boulware, David R
Format: Journal Article
Language:English
Published: US Oxford University Press 01.02.2021
Subjects:
Brief Report
Editor's Choice
COVID-19
cohort
coronavirus
fluvoxamine
SARS-COV-2
ISSN:2328-8957, 2328-8957
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation. We report a real-world experience using fluvoxamine for early COVID-19. Incidence of hospitalization was 0% (0/65) with fluvoxamine and 12.5% (6/48) with observation alone. At 14 days, residual symptoms persisted in 0% (0/65) with fluvoxamine and 60% (29/48) with observation.
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Report-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofab050